Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e nn » e non (Expand Search), _ nn (Expand Search), k nn (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e nn » e non (Expand Search), _ nn (Expand Search), k nn (Expand Search)
-
8041
THS exposure in conjunction with antioxidant treatment for 2.5 and 5 months alleviates metabolic syndrome in a dose-dependent manner.
Published 2016“…<p><b>(A)</b> THS-exposed mice treated with antioxidants for 5 months have reduced visceral fat accumulation compared to THS exposed mice. …”
-
8042
-
8043
-
8044
-
8045
-
8046
-
8047
Table 2_Fatal HLH in patients with X-linked lymphoproliferative disease 1 due to a novel variant in SH2D1A: case report.docx
Published 2025“…</p>Objective<p>Present a clinical case of fatal HLH associated with a novel SH2D1A variant, highlighting the variability of clinical presentation and the potential role of co-infections.…”
-
8048
Table 1_Fatal HLH in patients with X-linked lymphoproliferative disease 1 due to a novel variant in SH2D1A: case report.docx
Published 2025“…</p>Objective<p>Present a clinical case of fatal HLH associated with a novel SH2D1A variant, highlighting the variability of clinical presentation and the potential role of co-infections.…”
-
8049
Table 3_Fatal HLH in patients with X-linked lymphoproliferative disease 1 due to a novel variant in SH2D1A: case report.docx
Published 2025“…</p>Objective<p>Present a clinical case of fatal HLH associated with a novel SH2D1A variant, highlighting the variability of clinical presentation and the potential role of co-infections.…”
-
8050
Validation of RNA-sequencing by Q-PCR and effects of 5Aza-dC on a subset of DM and DE genes in CESC and OESC.
Published 2017“…<b>A)</b> The relative expression of <i>SLC22A23</i> under treatment with 5aza-dC increases in CESC as well as in OESC. …”
-
8051
-
8052
-
8053
MCP-1-deficiency decreased CD11c-expressing cells via impairing the production of ROS and decreased activation of PLCγ2, Akt, and ERK upon M-CSF stimulation in BMM.
Published 2013“…<p>BMMs from WT (open bar) and MCP-1-KO mice (oblique-lined bar) were incubated in the presence of M-CSF (30 ng/ml) with U73122 (10 µM), Akt inhibitor IV (0.3 µM), PD098059 (5 µM), DPI (50 nM), NAC (3 mM), or H<sub>2</sub>O<sub>2</sub> (300 µM) for 4 d (A). *, <i>P</i><0.05; ***, <i>P</i><0.001 compared with vehicle-treated WT cells. …”
-
8054
-
8055
-
8056
-
8057
-
8058
-
8059
Characteristics between group 3 and group 4 as differentiated during radiologic follow-up.
Published 2021Subjects: -
8060
Patient characteristics categorized according to baseline pneumonia extent.
Published 2021Subjects: